Tumor-infiltrating lymphocyte (TIL) therapy: A new approach to fighting cancer
In Canada, 2 out of 5 persons will receive a cancer diagnosis in their lifetime, but certain types of cancer are still resistant to current treatments.
Collect immune cells already present in the patient’s tumor, multiply them in the laboratory, and then transfuse them so they can attack the cancer with ten times the potency.
Your support makes it possible to treat the first patients who have exhausted all other treatment options with TIL therapy, as well as position the CHUM as a leader in this oncology breakthrough.
